Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilgenhof, Sofie, Four, Stephanie Du, Everaert, Hendrik, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536036/
https://www.ncbi.nlm.nih.gov/pubmed/23043499
http://dx.doi.org/10.3109/07357907.2012.727934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536036/
https://www.ncbi.nlm.nih.gov/pubmed/23043499
http://dx.doi.org/10.3109/07357907.2012.727934

Ejemplares similares